Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of rabeprazole on BMS-986165 pharmacokinetics in healthy volunteers
NL-OMON47975Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of deucravacitinib and rabeprazole in psoriasis, systemic lupus erythematosus (SLE) and Crohn's disease, sponsored by Bristol Myers Squibb. Primary endpoints: BMS-986165 maximum observed plasma concentration, BMS-986165 area under the concentration-time curve from time zero to last quantifiable concentration and 1 more. Started May 2019; status: completed.
02
Drugs
deucravacitinibrabeprazole
03
Conditions
psoriasissystemic lupus erythematosus (SLE)Crohn's disease
Beyond the preview
Go deeper on NL-OMON47975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47975.